Juntendo Medical Journal, 2026 Reviews Juntendo Medical Journal 2026 Revisiting the Concept of DIC: A Phenotype-guided Framework for Modern Hemostatic Medicine Tomaz CROCHEMORE1, 2) Ecaterina SCARLATESCU3, 4) 1)Department of critical care, Hospital Moriah, São Paulo, Brazil 2)Department of critical care, Hospital São Luiz Itaim, Rede Dor, São Paulo, Brazil 3)Carol Davila University of Medicine and Pharmacy, Bucharest, Romania 4)Department of Anesthesia and Intensive Care III, Fundeni Clinical Institute, Bucharest, Romania TEL: +55-11-96655-1410 〔Received E-mail: tomazcr@gmail.com Dec. 5, 2025〕 〔Accepted Dec. 11, 2025〕 J-STAGE Advance published date: Feb. 17, 2026 Copyright © 2026 The Juntendo Medical Society. This is an open access article distributed under the terms of Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original source is properly credited. doi: 10.14789/ejmj.JMJ25-0066-R 1 Crochemore T, Scarlatescu E: Phenotype-guided approach to DIC hypocoagulopathy, often after irreversible organ failure has begun and therefore fail to identify earlier, potentially reversible phases of the coagulopathy spectrum2). Recent evidence reinforces the concept of the coagulation system as a functional and adaptive organ, tightly interconnected with vascular, inflam­ matory, and immune pathways. Its alterations are graded, dynamic, and context-dependent, rather than a binary state of “normal versus DIC”3). Instead of representing a single disease entity, DIC should be understood as a spectrum of pathophysiologic processes driven by the nature and intensity of the underlying insult4). Consequently, labeling a patient as “overt DIC” offers limited therapeutic value, risks overlooking intermediate phenotypes, and may delay timely, mechanism-based intervention5). The evolution from DIC to induced coagulopa­ thies mirrors paradigm shifts in other organ-failure syndromes6, 7). Just as “acute respiratory distress syndrome” replaced the vague concept of “shock lung,” and “acute kidney injury” supplanted “uremic syndrome,” we now recognize that “DIC” is an umbrella term concealing disease-specific mecha­ nisms that demand individualized treatment strat­ egies8). This narrative review proposes an etiologic and phenotype-guided framework (SIC, TIC, CAC, OAC, and EIC) that replaces the generic label ‘DIC’ with context-specific, induced coagulopathies and links these entities to distinct laboratory and clin­ ical phenotypes amenable to targeted therapy2, 9, 10). Each entity exhibits unique triggers, endothelial responses, and hemostatic trajectories that can be recognized in real time using viscoelastic testing (VET) and endothelial biomarkers (e.g., D-dimer, protein C, antithrombin, PAI-1). This precision approach underpins goal-directed hemostatic therapy, aiming to prevent progression to organ failure and reduce both thrombotic and hemor­ rhagic complications2, 11-13). From DIC to a framework of pathology-induced coagulopathies(SIC, TIC, CAC, OAC, and EIC) Among the many precipitants of coagulopathy, sepsis remains the most common and best charac­ terized2). In 2017, the concept of sepsis-induced coagulopathy (SIC) was introduced, and by 2019, it was formally adopted by the ISTH Scientific and 2 Standardization Committee as the early phase of DIC14, 15). The SIC score, derived from platelet count, PT-INR, and the Sequential Organ Failure Assess­ ment (SOFA) score, enables early recognition of compensated coagulation disturbance before overt consumption occurs15). The same rationale applies to trauma-induced coagulopathy (TIC), ECMO-induced coagulopathy (EIC), cancer-associated coagulopathy (CAC), obst­ etric-associated coagulopathy (OAC), and other context-specific entities. Each begins with endo­ thelial activation and tissue-factor release, followed by thrombin generation, suppression of natural anticoagulant pathways, and dysregulated fibrino­ lysis. Yet the magnitude, timing, and clinical expres­ sion of these events differ substantially: • In sepsis, intense immune activation and glyco­ calyx degradation drive an early hypercoagu­ lable and hypofibrinolytic phenotype16); • In trauma, shock-related hypoperfusion and tissue disruption precipitate an early and robust fibrinolytic surge, a hallmark of trauma-induced coagulopathy17); •E  CMO support induces concurrent prothrom­ botic and consumptive mechanisms driven by blood-circuit interaction and systemic inflam­ mation, resulting in a dynamic state of mixed hypo- and hypercoagulability10); • In obstetric complications, placental disruption, massive tissue-factor release, and endothelial injury precipitate abrupt hypercoagulability that may rapidly evolve into consumptive coag­ ulopathy (e.g., PPH, abruption, amniotic fluid embolism)18); • In cancer-associated coagulopathy, tumorrelated tissue factor expression, NETosis, and chronic endothelial activation sustain a persistent hypercoagulable and hypofibrinolytic state, incr­ easing the risk of both macro- and microvas­ cular thrombosis19); Recognizing these entities as induced, contextspecific coagulopathies underscores why a single, late-stage term such as ‘DIC’ is conceptually and therapeutically insufficient. By focusing on the causative trigger and hemostatic phenotype, clini­ cians can tailor therapy, anticoagulant, antifibrino­ lytic, or hemostatic, according to the stage of disease, rather than applying uniform treatment to all patients labeled as DIC20). Juntendo Medical Journal, 2026 Dynamic pathophysiology: from thromboinflammation to hemostatic failure Endothelial injury and the glycocalyx: the hidden origin of coagulopathy Hemostasis operates as an adaptive defense mech­ anism designed to contain infection and restore vascular integrity. When dysregulated, this defense transforms into generalized thromboinflammation21). The interaction between leukocytes, platelets, and the vascular endothelium drives the transition from localized protection to systemic injury22). Initial phase: Pro-inflammatory cytokines, such as TNF-α, IL-1β, and IL-6, trigger the expression of tissue factor in monocytes and endothelium, ampli­ fying thrombin generation23). Natural anticoagulant pathways including antithrombin, protein C, and tissue factor pathway inhibitor, are suppressed, while the endothelial glycocalyx begins to degrade24). The result is macrovascular hypercoagulability charac­ terized by elevated levels of D-dimer and fibrin­ ogen, phenotype of thrombotic coagulopathy due to hypercoagulability25). Intermediate phase: Excess plasminogen activator inhibitor-1 (PAI-1) suppresses fibrinolysis, leading to fibrinolysis shutdown and microvascular throm­ bosis. Subsequent organ hypoperfusion manifests as early organ dysfunction induced by sepsis26)-phe­ notype of thrombotic coagulopathy due to fibrino­ lysis shutdown. Late phase: Persistent inflammation leads to consu­ mption of coagulation factors, fibrinogen and throm­ bocytopenia, characterizing a hypocoagulable state, associated with hemorrhagic manifestations-phe­ notype of hemorrhagic coagulopathy due to hypo­ coagulability. When PAI-1 stores are depleted, hyperfibrinolysis can be the final mechanism of coagulopathy-the phenotype of hemorrhagic coag­ ulopathy due to hyperfibrinolysis27). Bleeding becomes clinically significant at this terminal stage, the tradi­tional “overt DIC”28). These phases correspond to discrete thrombotic, fibrinolytic-shutdown, and hemorrhagic phenotypes, which offer more actionable therapeutic targets than the unitary diagnosis of DIC. Therefore, what we have historically diagnosed as DIC represents only the final moment of a continuum that begins with endothelial activation and ends in hemostatic exhaustion. Recognizing the specific phenotype of each stage is essential for targeted therapy29). The vascular endothelium, lined by a fragile glyco­ calyx composed of proteoglycans and glycosamino­ glycans, maintains vascular homeostasis, providing an antithrombotic and anti-inflammatory surface16). During sepsis or trauma, enzymatic degradation and oxidative stress disrupt this barrier, exposing adhe­ sion molecules such as E-selectin and ICAM-1. This promotes leukocyte and platelet adhesion, micro­ thrombus formation, and capillary extravasation30). Loss of glycocalyx integrity increases vascular permeability, promotes interstitial edema, and ampli­ fies the systemic inflammatory response. Circu­ lating glycocalyx degradation products, such as syndecan-1 and heparan sulfate, have emerged as biomarkers of endothelial injury and correlate strongly with disease severity and outcomes31). The destruction of this microvascular interface explains the heterogeneous coagulation profiles observed in sepsis. Although conventional coagula­ tion tests (CCTs) may suggest the presence of hypo­ coagulation, recent studies show that VET allow differentiation between hyper- and hypocoagula­ bility, and concomitant fibrinolytic imbalance32). These observations support a shift from viewing coagulopathy purely as factor deficiency toward a paradigm in which endothelial integrity largely determines the hemostatic phenotype. By integrating endothelial biomarkers with VET, physicians can monitor the transition from throm­ botic to hemorrhagic states in real time, allowing phenotype-guided hemostatic management long before conventional DIC scores become abnormal33). Clinical and laboratory evidence supporting the phenotype-based model Viscoelastic profiling: seeing beyond conventional coagulation tests Conventional coagulation tests (CCTs), such as prothrombin time (PT), activated partial thrombop­ lastin time (aPTT), fibrinogen concentration, provide static, plasma-based information that does not capture the cellular and dynamic features of in vivo coagulation34). Viscoelastic assays (ROTEM/TEG) allow real-time assessment of clot initiation, propa­ gation, firmness, and lysis, thus offering a more physiologically relevant picture of hemostasis35). 3 Crochemore T, Scarlatescu E: Phenotype-guided approach to DIC Several studies have demonstrated marked disc­ ordance between CCTs and viscoelastic findings in critically ill and septic patients. In a large ICU cohort, more than half of critically ill patients exhib­ ited normal viscoelastic profiles despite abnormal PT/aPTT or thrombocytopenia, which frequently prompted fresh frozen plasma (FFP) or platelet transfusion in the absence of viscoelastic evidence of hypocoagulability36). This pivotal study under­ scores that coagulopathy defined by CCTs may not represent true hypocoagulability, and that visco­ elastic monitoring can prevent inappropriate trans­ fusion and improve individualized hemostatic care37). In a prospective cohort of 161 patients with sepsis or septic shock, 72.7 % demonstrated coagulopathy by ROTEM, subdivided into 25.5% hypercoagulable, 54.7% hypocoagulable, and 13.6% mixed patterns38). Even among patients with prolonged PT/INR, visc­ oelastic analysis frequently revealed preserved or increased clot firmness, indicating ongoing thrombin generation and fibrin polymerization. FIBTEMMCF strongly correlated with fibrinogen levels (ρ = 0.73), while EXTEM and INTEM parameters reflected platelet and thrombin-mediated effects38). Another observational study confirmed that pati­ ents labeled as “hypocoagulable” by CCTs often displayed latent hypercoagulability on ROTEM, particularly when fibrinogen was elevated39). These findings illustrate that SIC is not unidirectional but fluctuates dynamically across thrombotic and hemo­ rrhagic states. Therefore, VET provides a real-time window into the evolving phenotype and should be used as a monitoring tool to tailor therapy, anticoagulation in early thrombotic phases and goal-directed hemo­ static resuscitation in later hemorrhagic stages40-43). Biomarker-guided phenotyping in sepsis-associated coagulopathy Thrombocytopenia Thrombocytopenia (TCP) represents both a diag­ nostic and prognostic marker in sepsis44). A progre­ ssive decline in platelet count reflects endothelial injury, increased platelet consumption through microvascular thrombosis, and immune-mediated destruction45). Severe TCP (<100 × 109/L) has been consistently associated with higher risk of septic shock and mortality46). Importantly, platelet count changes, rather than single values, carry superior 4 predictive power47), as highlighted in the 2024 narr­ ative review on sepsis-related TCP, which describes heterogeneous mechanisms ranging from cytokinedriven marrow suppression to macrophage-medi­ ated clearance48). A British prospective multicenter observational study reported a 35.4% mortality rate among ICU patients with severe TCP, underscoring its role as a strong marker of critical illness severity49). Thrombocytopenia is highly prevalent in sepsis, affecting between 22% and 58% of septic patients, depending on disease severity and timing of assess­ ment50). Its mechanisms are multifactorial, including cytokine-mediated bone marrow suppression, peri­ pheral consumption due to microvascular throm­ bosis, immune-mediated platelet destruction, hemo­ dilution, and splenic sequestration51). Clinically, TCP confers a dual risk profile: while severe reductions in platelet count predispose to bleeding, early micro­ thrombus formation and impaired fibrinolysis can paradoxically sustain or even amplify hypercoagu­ lability25). This complex interplay explains why TCP consistently correlates with worse outcomes, inclu­ ding greater organ dysfunction, prolonged ICU stay, and increased mortality52). Against this complex background, the finding that approximately 18-20% of septic shock patients with TCP demonstrated hypercoagulability on TEG is particularly noteworthy53). Despite reduced platelet counts, traditionally interpreted as a marker of hypocoagulability, a substantial subset of patients had preserved or even augmented clot strength. More importantly, hypercoagulability was indepe­ ndently associated with lower mortality (OR 0.395), suggesting that a maintained or compensatory coagulation response may reflect a more intact endothelial function and host-defense mechanism in early sepsis53). This observation challenges the conventional assumption that TCP uniformly indi­ cates bleeding risk and highlights the importance of phenotyping coagulation status rather than relying solely on platelet counts. Fibrinogen Fibrinogen functions both as an acute-phase reactant and as the substrate for fibrin formation, resulting in a characteristic biphasic pattern with early elevation and late consumption in sepsis. Early in sepsis, fibrinogen levels may rise due to IL-6- Juntendo Medical Journal, 2026 mediated hepatic synthesis, but progressive consu­ mption and hyperfibrinolysis can later result in hypofibrinogenemia54). Low fibrinogen (< 1.5 g/L) marks the transition from thrombotic to consump­ tive phenotype and correlates with bleeding risk and mortality55). Conversely, high fibrinogen levels in early sepsis are linked to hypercoagulability on VET , high clot firmness parameters, reflecting a compensatory phase prior to decompensation38). D-Dimer The D-dimer, a fibrin degradation product, remains one of the most widely used biomarkers of DIC56). Elevated levels reflect ongoing fibrin formation and lysis, but the magnitude of elevation carries distinct prognostic implications. High D-dimer concentra­ tions (> 4 mg/L FEU) are strongly correlated with septic shock and mortality57). In a large pediatric ICU cohort (n = 7,648), D-dimer demonstrated the highest predictive performance for in-hospital mort­ ality (AUROC = 0.77), surpassing PT, aPTT, and fibrinogen58). Meta-analysis evidence confirms its independent prognostic value across age groups and clinical settings, making D-dimer a corner­ stone biomarker for risk stratification in SIC59). Protein C Protein C (PC) has emerged as one of the most robust prognostic biomarkers in sepsis, with consis­ tently lower levels observed in non-survivors comp­ ared to survivors60). The systematic review and meta-analysis by Catenacci et al. demonstrated a significant standardized mean difference favoring higher PC levels in survivors (SMD 0.52, 95% CI 0.24-0.81), with similar patterns confirmed in 28day mortality analyses (SMD 0.44, 95% CI 0.260.61)61). These data indicate that a decline in PC is asso­ ciated with progressive endothelial dysfunction and a reduction in natural anticoagulant capacity. Serial measurement of PC could therefore serve as a dynamic marker of transition from compensated to decompensated coagulopathy25). Integrating PC levels, platelet count, PT-INR, and viscoelastic findings may improve risk stratification and help identify candidates for therapies aimed at restoring endothelial anticoagulant function, such as antithrombin or recombinant thrombomodulin62). Antithrombin Decreased antithrombin (AT) levels are one of the most consistent findings in sepsis and are stro­ ngly associated with the severity of organ dysfunc­ tion and mortality63). The consumption of AT results from its continuous neutralization of thrombin and factor Xa, combined with impaired hepatic synthesis and degradation by neutrophil elastase64). In severe sepsis, AT activity often drops below 70%, which correlates with disseminated microthrombosis and poor outcomes65). Restoration of AT activity through substitution therapy has been linked to improved 28-day survival in patients with sepsis-associated DIC when anticoagulant therapy is guided by biomarker-based stratification66). Plasminogen Activator Inhibitor-1 (PAI-1) Among the fibrinolysis regulators, plasminogen activator inhibitor-1 (PAI-1) plays a pivotal role in defining the early thrombotic phenotype of SIC. Elevated PAI-1 levels inhibit both tissue- and urokinase-type plasminogen activators, suppressing fibrinolysis and promoting microvascular fibrin deposition67). Multiple observational studies have demonstrated that high PAI-1 concentrations corr­ elate with organ dysfunction, DIC progression, and mortality68-70). In a multicenter cohort, PAI-1 levels ≥ 48.7 ng/mL predicted sepsis-associated liver dysf­ unction, while values ≥ 83 ng/mL were independe­ ntly associated with 28-day mortality and DIC development70). A 2023 systematic review and meta-analysis encompassing over 4,000 patients confirmed that non-survivors exhibit significantly higher PAI-1 concentrations, establishing it as one of the most powerful independent biomarkers of severity and outcome in sepsis71). From a mechanistic standpoint, PAI-1 links endothelial activation to fibrinolytic shutdown, bridging the transition from hypercoag­ ulability to microvascular thrombosis72). Therefore, serial PAI-1 assessment, combined with viscoelastic lysis indices, can delineate fibrinolytic phenotypes and guide timing of anticoagulant or fibrinolytic modulation in precision hemostatic management26). Synthesis Taken together, progressive TCP, declining fibri­ nogen, reduced PC and AT activities, accompanied by markedly elevated D‑dimer and PAI‑1 concen­ 5 Crochemore T, Scarlatescu E: Phenotype-guided approach to DIC trations, define a distinct biochemical and functional signature of advanced SIC25, 73). The integration of these biomarkers, rather than their isolated interpretation, captures the dynamic interplay between excessive thrombin generation, impaired fibrin formation, depletion of natural anti­ coagulants, and dysregulated fibrinolysis. When combined with viscoelastic assays, which provide real-time assessment of clot initiation, propagation, stabilization, and lysis within the cellular coagula­ tion model, this composite hemostatic profile enables precise phenotyping of coagulopathy trajectories and the identification of optimal therapeutic windows for antithrombotic, fibrinolytic, or pro-hemostatic interventions74). This biomarker-driven and phenotype-guided strategy reflects a shift from the traditional descrip­ tive view of DIC to a modern conceptual framework of pathology-induced coagulopathies, fully aligned with the principles of precision hemostatic medi­ cine32, 41, 75). Thrombotic and hemorrhagic phenotypes in critical illness Recent expert consensus distinguishes two domi­ nant clinical phenotypes of coagulopathy in critically ill patients75): 1. T  hrombotic coagulopathies, marked by systemic hypercoagulability and hypofibrinolytic states, typical of early sepsis, late trauma, or cancer. 2. H  emorrhagic coagulopathies, characterized by hypocoagulation and/or hyperfibrinolysis, obse­ rved in late-stage sepsis, obstetric catastrophe, early trauma or massive transfusion. Patients often oscillate between these phenotypes according to disease evolution and therapeutic inter­ ventions75). The point at which patients transition from thro­ mbotic to hemorrhagic phenotypes corresponds to hemostatic exhaustion and has traditionally been captured by the label ‘DIC’, despite representing opposite physiologic states along a continuum. Recognizing this continuum emphasizes the need to re-evaluate the term DIC: it merges contrasting physiological conditions into a single vague label and does not provide clarity for treatment options. Toward phenotype-guided hemostatic therapy The management of coagulopathy should follow 6 the principle of treating the mechanism, not the score. A phenotype-guided framework can be summ­ arized as follows: 1. E  tiologic classification — Identify the trigger: sepsis (SIC), trauma (TIC), ECMO (EIC), cancer (CAC), or obstetrics (OAC). 2. P  henotypic definition — Determine the hemo­ static profile via VET, platelet function, fibrin­ ogen, D-dimer, PC, AT and PAI-1: • Thrombotic (hypercoagulable, fibrinolytic shutdown) • Hemorrhagic (hypocoagulable, hyperfibri­ nolytic) • Mixed/transition state. 3. Targeted intervention • Thrombotic phenotype: consider heparin, antithrombin, or recombinant thrombomod­ ulin; maintain normothermia and avoid proc­ oagulant transfusions76); • Fibrinolytic-shutdown phenotype: explore modulation strategies (thrombomodulin, cautious fibrinolytic therapy)29); • Hemorrhagic phenotype: implement goaldirected hemostatic resuscitation guided by viscoelastic endpoints11). This phenotype-driven strategy integrates coag­ ulation monitoring, pathophysiologic mechanisms, and individualized therapy to mitigate both throm­ botic and bleeding complications. Conclusion: the epitaph of DIC and the rise of hemostatic precision medicine Disseminated intravascular coagulation, once regarded as a discrete and universal clinical entity, is now recognized as the common final pathway of multiple induced coagulopathies. Persisting with the DIC label alone risks obscuring early patho­ physiological transitions, delaying timely interven­ tion, and reinforcing a reactive rather than antici­ patory approach to hemostatic management. A shift toward a phenotype-driven, etiologybased lexicon (e.g., SIC, TIC, EIC, CAC and OAC), acknowledges that what has been termed ‘DIC’ is the common end point of diverse induced coagulop­ athies rather than a single disease and offers a more accurate and clinically actionable framework. Through dynamic coagulation system monitoring, integrating the thrombotic profile (D-dimer, fibrin­ ogen, platelet count), endothelial dysfunction markers Juntendo Medical Journal, 2026 (PC, AT, PAI-1), and viscoelastic assays, clinicians can monitor the evolving hemostatic profiles in real time, identify the dominant and transitional pheno­ types, and implement targeted interventions at the optimal therapeutic window. This transformation signals the rise of hemostatic precision medicine, where coagulation is understood as a dynamic organ system rather than a static set of laboratory abnormalities. Future research should validate phenotype-spe­ cific therapeutic algorithms, leverage machinelearning approaches for real-time prediction of phenotype transitions, and establish international registries to refine criteria for SIC, TIC, and related entities across heterogeneous populations. Acknowledgments Not applicable. Funding The authors received no financial support for the research. Data availability This article is a narrative review and does not involve the generation or analysis of any original datasets. All information presented is derived from publicly available published studies. Author contributions TC conceived the study, originated the conceptual framework, developed the phenotype-guided inter­ pretation of disseminated coagulopathies, conducted the literature review, interpreted all scientific evidence, and was the major contributor in writing the manuscript. ES critically reviewed the manu­ script for intellectual content and contributed to scientific refinement and structural clarity. All authors read and approved the final manuscript. Conflicts of interest statement The authors declare that there are no conflicts of interest. References 1) Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M; Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH): Towards defini­ tion, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost, 2001; 86: 1327-1330. 2) Iba T, Helms J, Connors JM, Levy JH: The pathophys­ iology, diagnosis, and management of sepsis-associated disseminated intravascular coagulation. J Intensive Care, 2023; 11: 24. 3) Wilhelm G, Mertowska P, Mertowski S, et al: The Crossroads of the Coagulation System and the Immune System: Interactions and Connections. Int J Mol Sci, 2023; 24: 12563. 4) Unar A, Bertolino L, Patauner F, Gallo R, DuranteMangoni E: Pathophysiology of Disseminated Intravas­ cular Coagulation in Sepsis: A Clinically Focused Over­ view. Cells, 2023; 12: 2120. 5) Iba T, Levi M, Thachil J, Helms J, Scarlatescu E, Levy JH: Communication from the Scientific and Standard­ ization Committee of the International Society on Throm­ bosis and Haemostasis on sepsis-induced coagulopathy in the management of sepsis. J Thromb Haemost, 2023; 21: 145-153. 6) Yang H, Ma X, Li X: The diagnosis of DIC: a current overview. Front Med (Lausanne), 2025; 12: 1502628. 7) Thachil J, Iba T, Scarlatescu E, Levy JH: Why is DIC a Rare Diagnosis in the 21st Century? Juntendo Iji Zasshi, 2024; 70: 121-124. 8) Papageorgiou C, Jourdi G, Adjambri E, et al: Dissemi­ nated Intravascular Coagulation: An Update on Patho­ genesis, Diagnosis, and Therapeutic Strategies. Clin Appl Thromb Hemost, 2018; 24(9_suppl): 8S-28S. 9) Kornblith LZ, Moore HB, Cohen MJ: Trauma-induced coagulopathy: The past, present, and future. J Thromb Haemost, 2019; 17: 852-862. 10) Levy JH, Alexander PMA, Wolberg AS, et al: ECMOinduced coagulopathy: strategic initiatives for research and clinical practice (a workshop report of the NHLBI). Blood Vessel Thromb Hemost, 2025; 2: 100064. 11) Crochemore T, Görlinger K, Lance MD: Early GoalDirected Hemostatic Therapy for Severe Acute Bleeding Management in the Intensive Care Unit: A Narrative Review. Anesth Analg, 2024; 138: 499-513. 12) Kato H, Hagihara M, Asai N, et al: Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsis-induced disseminated intravas­ cular coagulation-A meta-analysis. Thromb Res, 2023; 226: 165-172. 13) Iba T, Nagaoka I, Boulat M: The anticoagulant therapy for sepsis-associated disseminated intravascular coag­ ulation. Thromb Res, 2013; 131: 383-389. 14) Iba T, Levi M, Levy JH: Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. Semin Thromb Hemost, 2020; 46: 89-95. 15) Iba T, Nisio MD, Levy JH, Kitamura N, Thachil J: New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ Open, 2017; 7: e017046. 16) Iba T, Levy JH: Derangement of the endothelial glyco­ calyx in sepsis. J Thromb Haemost, 2019; 17: 283-294. 17) Moore EE, Moore HB, Kornblith LZ, et al: Traumainduced coagulopathy. Nat Rev Dis Primers, 2021; 7: 30. 18) Erdoes G, Faraoni D, Koster A, Steiner ME, Ghadimi K, Levy JH: Perioperative Considerations in Manage­ ment of the Severely Bleeding Coagulopathic Patient. Anesthesiology, 2023; 138: 535-560. 19) Van Dreden P, ΕlalamyΙ, Gerotziafas GT: The Role of Tissue Factor in Cancer-Related Hypercoagulability, 7 Crochemore T, Scarlatescu E: Phenotype-guided approach to DIC Tumor Growth, Angiogenesis and Metastasis and Future Therapeutic Strategies. Crit Rev Oncog, 2017; 22: 219248. 20) Iba T, Levi M, Thachil J, Levy JH: Disseminated Intra­ vascular Coagulation: The Past, Present, and Future Considerations. Semin Thromb Hemost, 2022; 48: 978987. 21) Batista VL, Martins JR, Queiroz-Junior CM, et al: Mechanisms of Thromboinflammation in Viral Infec­ tions-A Narrative Review. Viruses, 2025; 17: 1207. 22) Dehghani T, Panitch A: Endothelial cells, neutrophils and platelets: getting to the bottom of an inflammatory triangle. Open Biol, 2020; 10: 200161. 23) Nie , Zhou L, Tian W, et al: Deep insight into cytokine storm: from pathogenesis to treatment. Signal Trans­ duct Target Ther, 2025; 10: 112. 24) Maneta E, Aivalioti E, Tual-Chalot S, et al: Endothelial dysfunction and immunothrombosis in sepsis. Front Immunol, 2023; 14: 1144229. 25) Tsantes AG, Parastatidou S, Tsantes EA, et al: SepsisInduced Coagulopathy: An Update on Pathophysiology, Biomarkers, and Current Guidelines. Life (Basel), 2023; 13: 350. 26) Schmitt F, Manolov V, Morgenstern JCF, et al: Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: results of an observational pilot study. Ann Intensive Care, 2019; 9: 19. 27) Costantini TW, Kornblith LZ, Pritts T, Coimbra R: The intersection of coagulation activation and inflammation after injury: What you need to know. J Trauma Acute Care Surg, 2024; 96: 347-356. 28) Gando S, Levi M, Toh CH: Disseminated intravascular coagulation. J Intensive Care, 2025; 13: 32. 29) Gong F, Zheng X, Zhao S, et al: Disseminated intravas­ cular coagulation: cause, molecular mechanism, diagnosis, and therapy. MedComm (2020), 2025; 6: e70058. 30) Wang R, Han Q, Fan J, et al: Sepsis-Induced Endothe­ lial Barrier Dysfunction: Mechanisms, Pathology, and Therapeutic Advances. Research (Wash D C), 2025; 8: 0997. 31) Wu Q, Gao W, Zhou J, et al: Correlation between acute degradation of the endothelial glycocalyx and microcir­ culation dysfunction during cardiopulmonary bypass in cardiac surgery. Microvasc Res, 2019; 124: 37-42. 32) Scarlatescu E, Juffermans NP, Thachil J: The current status of viscoelastic testing in septic coagulopathy. Thromb Res, 2019; 183: 146-152. 33) Müller MC, Meijers JC, Vroom MB, Juffermans NP: Utility of thromboelastography and/or thromboelasto­ metry in adults with sepsis: a systematic review. Crit Care, 2014; 18: R30. 34) Whitton TP, Healy WJ: Review of Thromboelastography (TEG): Medical and Surgical Applications. Ther Adv Pulm Crit Care Med, 2023; 18: 29768675231208426. 35) Franchini M, Mengoli C, Cruciani M, et al: The use of viscoelastic haemostatic assays in non-cardiac surgical settings: a systematic review and meta-analysis. Blood Transfus, 2018; 16: 235-243. 36) Crochemore T, Corrêa TD, Lance MD, et al: Throm­ boelastometry profile in critically ill patients: A singlecenter, retrospective, observational study. PLoS One, 2018; 13: e0192965. 37) Bareille M, Hardy M, Douxfils J, et al: Viscoelastometric Testing to Assess Hemostasis of COVID-19: A System­ 8 atic Review. J Clin Med, 2021; 10: 1740. 38) Bui-Thi HD; Kien To Gia. Electronic address: togiakien @ump.edu.vn; Le Minh K. Coagulation profiles in patients with sepsis/septic shock identify mixed hypohypercoagulation patterns based on rotational throm­ boelastometry: A prospective observational study. Thromb Res, 2023; 227: 51-59. 39) Bui-Thi HD, Nguyen DK, To GK, et al: Uncovering hypercoagulation status using rotational thromboelas­ tometry in patients with sepsis presented with hypo­ coagulation based on conventional coagulation tests: an observational study. Eur Rev Med Pharmacol Sci, 2023; 27: 4492-4503. 40) Volod O, Bunch CM, Zackariya N, et al: Viscoelastic Hemostatic Assays: A Primer on Legacy and New Generation Devices. J Clin Med, 2022; 11: 860. 41) Reardon B, Pasalic L, Favaloro EJ: The Role of Visco­ elastic Testing in Assessing Hemostasis: A Challenge to Standard Laboratory Assays? J Clin Med, 2024; 13: 3612. 42) Casselman FPA, Lance MD, Ahmed A, et al: 2024 EACTS/EACTAIC Guidelines on patient blood mana­ gement in adult cardiac surgery in collaboration with EBCP. Eur J Cardiothorac Surg, 2025; 67: ezae352. 43) Halvorsen S, Lance MD, Ahmed A, et al: 2022 ESC Guidelines on cardiovascular assessment and manage­ ment of patients undergoing non-cardiac surgery. Eur Heart J, 2022; 43: 3826-3924. 44) Setarehaseman A, Mohammadi A, Maitta RW: Throm­ bocytopenia in Sepsis. Life (Basel), 2025; 15: 274. 45) Yang X, Song J, Ma H, et al: The Crucial Roles of Plate­ lets as Immune Mediators in Sepsis. J Inflamm Res, 2025; 18: 12825-12845. 46) Zhou Z, Feng T, Xie Y, et al: Prognosis and rescue therapy for sepsis-related severe thrombocytopenia in critically ill patients. Cytokine, 2020; 136: 155227. 47) Si Y, You S, Lei Q, Liu C, Zhang J: Time series analysis between platelet counts and 60-day mortality in sepsis patients with thrombocytopenia: a retrospective cohort study. BMC Infect Dis, 2025; 25: 1084. 48) Satoh K, Wada T, Tampo A, et al: Practical approach to thrombocytopenia in patients with sepsis: a narra­ tive review. Thromb J, 2024; 22: 67. 49) Stanworth SJ, Walsh TS, Prescott RJ, Lee RJ, Watson DM, Wyncoll DL; Intensive Care Study of Coagulop­ athy Investigators: Thrombocytopenia and platelet transfusion in UK critical care: a multicenter observa­ tional study. Transfusion, 2013; 53: 1050-1058. 50) Jiménez-Zarazúa O, González-Carrillo PL, VélezRamírez LN, et al: Survival in septic shock associated with thrombocytopenia. Heart Lung, 2021; 50: 268-276. 51) Bedet A, Razazi K, Boissier F, et al: Mechanisms of Thrombocytopenia During Septic Shock: A Multiplex Cluster Analysis of Endogenous Sepsis Mediators. Shock, 2018; 49: 641-648. 52) Pène F, Russell L, Aubron C: Thrombocytopenia in the intensive care unit: diagnosis and management. Ann Intensive Care, 2025; 15: 25. 53) Kim SM, Kim SI, Yu G, Kim JS, Hong SI, Kim WY: Hypercoagulability in Septic Shock Patients With Throm­ bocytopenia. J Intensive Care Med, 2022; 37: 721-727. 54) Wolberg AS: Fibrinogen and fibrin: synthesis, structure, and function in health and disease. J Thromb Haemost, 2023; 21: 3005-3015. 55) Chen M, Chen X, Ling H, et al: Prognostic significance Juntendo Medical Journal, 2026 of fibrinogen levels in sepsis-associated acute kidney injury: unveiling a nonlinear relationship and clinical implications. Front Nephrol, 2024; 4: 1398386. 56) Qu X, Wang S, Ye X, Jiang G, Kuerban M, Xie Q: Prog­ nostic value of baseline plasma D-dimer levels in sepsis: a prospective cohort study. Pract Lab Med, 2025; 46: e00498. 57) Rodelo JR, De la Rosa G, Valencia ML, et al: D-dimer is a significant prognostic factor in patients with suspected infection and sepsis. Am J Emerg Med, 2012; 30: 19911999. 58) Wang G, Liu J, Xu R, Liu X: Elevated plasma D-dimer levels are associated with the poor prognosis of criti­ cally ill children. Front Pediatr, 2022; 10: 1001893. 59) Yang C, Zeng HH, Huang J, Zhang QY, Lin K: Predic­ tive roles of D-dimer for mortality of patients with community-acquired pneumonia: a systematic review and meta-analysis. J Bras Pneumol, 2021; 47: e20210072. 60) He RR, Yue GL, Dong ML, Wang JQ, Cheng C: Sepsis Biomarkers: Advancements and Clinical ApplicationsA Narrative Review. Int J Mol Sci, 2024; 25: 9010. 61) Catenacci V, Sheikh F, Patel K, Fox-Robichaud AE: The prognostic utility of protein C as a biomarker for adult sepsis: a systematic review and meta-analysis. Crit Care, 2022; 26: 21. 62) Williams B, Zou L, Pittet JF, Chao W: Sepsis-Induced Coagulopathy: A Comprehensive Narrative Review of Pathophysiology, Clinical Presentation, Diagnosis, and Management Strategies. Anesth Analg, 2024; 138: 696711. 63) Niederwanger C, Hell T, Hofer S, et al: Antithrombin deficiency is associated with mortality and impaired organ function in septic pediatric patients: a retrospec­ tive study. PeerJ, 2018; 6: e5538. 64) Semeraro N, Ammollo CT, Semeraro F, Colucci M: Sepsis-associated disseminated intravascular coagula­ tion and thromboembolic disease. Mediterr J Hematol Infect Dis, 2010; 2: e2010024. 65) Wei Q, Wang M, Peng X, Yang J, Niu T: Comparison of Three Different Disseminated Intravascular Coagu­ lation (DIC) Criteria and Diagnostic and Prognostic Value of Antithrombin Investigation in Patients with Confirmed Sepsis-Induced Coagulopathy (SIC). Clin Appl Thromb Hemost, 2024; 30: 10760296241271334. 66) Iba T, Tanigawa T, Wada H, Levy JH: The antithrombin activity recovery after substitution therapy is associ­ ated with improved 28-day mortality in patients with sepsis-associated disseminated intravascular coagula­ tion. Thromb J, 2023; 21: 112. 67) Curtiaud A, Iba T, Angles-Cano E, Meziani F, Helms J: Biomarkers of sepsis-induced coagulopathy: diag­ nostic insights and potential therapeutic implications. Ann Intensive Care, 2025; 15: 12. 68) Hoshino K, Kitamura T, Nakamura Y, et al: Usefulness of plasminogen activator inhibitor-1 as a predictive marker of mortality in sepsis. J Intensive Care, 2017; 5: 42. 69) Iba T, Thachil J: Clinical significance of measuring plas­ minogen activator inhibitor-1 in sepsis. J Intensive Care, 2017; 5: 56. 70) Woźnica-Niesobska E, Leśnik P, Janc J, Zalewska M, Łysenko L: The Role of Plasminogen Activator Inhibitor 1 in Predicting Sepsis-Associated Liver Dysfunction: An Observational Study. Int J Environ Res Public Health, 2023; 20: 4846. 71) Tipoe TL, Wu WKK, Chung L, et al: Plasminogen Acti­ vator Inhibitor 1 for Predicting Sepsis Severity and Mortality Outcomes: A Systematic Review and MetaAnalysis. Front Immunol, 2018; 9: 1218. 72) Hayakawa M, Tsuchida T, Honma Y, et al: Fibrinolytic system activation immediately following trauma was quickly and intensely suppressed in a rat model of severe blunt trauma. Sci Rep, 2021; 11: 20283. 73) Iba T, Levi M, Levy JH: Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. Semin Thromb Hemost, 2020; 46: 89-95. 74) Wool GD, Carll T: Viscoelastic testing: Critical appraisal of new methodologies and current literature. Int J Lab Hematol, 2023; 45: 643-658. 75) Helms J, Iba T, Connors JM, et al: How to manage coag­ ulopathies in critically ill patients. Intensive Care Med, 2023; 49: 273-290. 76) Kudo D, Goto T, Uchimido R, et al: Coagulation pheno­ types in sepsis and effects of recombinant human throm­ bomodulin: an analysis of three multicentre observa­ tional studies. Crit Care, 2021; 25: 114. 9